Shots:
- Telix Pharmaceuticals reported that the first pts. in the US have been dosed with Pixclara (floretyrosine F-18), marking the start of commercial availability of the FDA-approved PET imaging drug for glioma
- Pixclara (IV) is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients one month of age and older, in conjunction with other diagnostic evaluations
- The first commercial doses were administered in Indianapolis, Indiana, and Cleveland, Ohio, with PharmaLogic Holdings supplying finished unit doses to the US market; Pixclara is also being evaluated in a P-III study for potential expansion into brain metastases imaging
Ref: Telix | Image: Telix | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
